Brox A G, Howson-Jan K, Fauser A A
Department of Medicine, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada.
Br J Haematol. 1988 Nov;70(3):341-4. doi: 10.1111/j.1365-2141.1988.tb02492.x.
The treatment of idiopathic thrombocytopenic purpura (ITP) includes corticosteroids, danazol, splenectomy and various immunosuppressives. Treatment can be difficult for those patients refractory to these modalities and/or those patients intolerant of the secondary effects. In this paper we report on the use of ascorbate in the treatment of ITP and its successful use in seven of 11 patients studied. We found that therapy with ascorbate appeared to improve the platelet count and the intravascular survival of platelets. Because of excellent patient compliance and its lack of toxicity, it may be an alternative for the treatment of ITP. The exact role of ascorbate in the treatment of ITP, as well as its mechanism of action, await further study.
特发性血小板减少性紫癜（ITP）的治疗方法包括使用皮质类固醇、达那唑、脾切除术和各种免疫抑制剂。对于那些对这些治疗方式无效和/或对其副作用不耐受的患者，治疗可能会很困难。在本文中，我们报告了使用抗坏血酸治疗ITP的情况，并且在11例研究患者中有7例取得了成功。我们发现抗坏血酸治疗似乎能提高血小板计数和血小板的血管内生存期。由于患者依从性良好且无毒性，它可能是治疗ITP的一种替代方法。抗坏血酸在ITP治疗中的确切作用及其作用机制还有待进一步研究。
